Cupid shares hit fresh 52-week high as firm raises FY27 revenue, profit guidance again; multibagger stock skyrockets 617% in a year

Multibagger Cupid shares jumped to a fresh 52-week high on Thursday after the condom-maker announced the second increase in profit and revenue guidance in less than two weeks, with the company now expecting to post a revenue of Rs 800 crore and net profit of Rs 250 crore in the ongoing financial year 2027.

Cupid continues to witness strong business momentum in FY27, with Q2 FY27 total revenue expected to cross Rs 200 crore, the company said in a press release late on Wednesday. It added that the FY27 guidance was raised due to sustained momentum across its key business verticals and improved visibility across domestic and international markets. The shares gained nearly 1 % to Rs 313.90 apiece on NSE on Thursday.

The FY27 outlook has been revised upward, supported by strong Q2 FY27 business momentum expected to continue and grow through Q3 and Q4 FY27, improved visibility across institutional and private markets, continued expansion of the domestic FMCG business, progress towards imminent operationalisation of the Palava facility, and sustained growth across the Company's healthcare, and personal care portfolio, Cupid said.


This comes after the company last week raised its FY27 revenue guidance to Rs 725-750 crore and net profit guidance to Rs 210-225 crore. The company in less than two weeks has raised its revenue guidance by up to 10% and profit guidance by up to 19%.

Also read | Cupid among 3 stocks showing White Marubozu Pattern

What Cupid expects now

Looking ahead, Cupid expects to scale domestic FMCG distribution to deepen Cupid's presence across modern trade, general trade and pharmacy channels. It also plans to operationalise its Palava manufacturing facility to enhance production capacity, flexibility and supply capabilities across domestic and international markets. Expansion of healthcare and personal care portfolio through new products, regulatory approvals and wider commercialisation opportunities are also on the cards.

Cupid also aims to strengthen its international healthcare business by expanding institutional, government and private-market opportunities across geographies, as well as build regional manufacturing platforms through the proposed South African venture, creating a potential base for wider international market expansion. It also plans to explore strategic healthcare opportunities through partnerships and investments that complement Cupid's healthcare and personal care ecosystem.

The company manufactures and supplies male and female condoms, water-based lubricant jelly and IVD kits.

Also read | Cupid raises FY27 profit guidance, targets Rs 750 crore revenue

Cupid share price

Cupid shares have seen a sharp surge this year, with the multibagger stock rallying around 197% in 2026 so far. The shares of the company have gained more than 17% in one week and 13% in one month.

The stock, which recently got added to the Nifty Smallcap 250 index, skyrocketed 617% in just one year. In the longer term, the stock has delivered massive returns of more than 7,521% in three years and 13,335% in five years. The company has a market capitalisation of over Rs 19,381 crore.

Disclaimer: This article has been written by Debaroti Adhikary, who is not a SEBI-registered Research Analyst or an Investment Adviser. Debaroti Adhikary and his/her ‘relative(s)’ (as defined under Section 2(77) of the Companies Act, 2013) do not hold any financial interest in the companies mentioned in this article as of the date of publication. The views/recommendations mentioned in this article, wherever applicable, are those of the respective SEBI-registered Research Analyst/brokerage and have been reproduced/reported with due attribution. They should not be construed as the views or recommendations of The Economic Times Digital or the journalist. Readers are advised to consider the original research report and make their investment decisions based on their own assessment. Brokerage disclaimers here.